Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies

NCT02000934 is registered in ClinicalTrials.gov with Calithera Biosciences, Inc as lead sponsor.

NCT NCT02000934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02000934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies
Lead sponsor
Calithera Biosciences, Inc
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2013
Completion date
June 29, 2021
Enrollment
143 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor and lymphoma malignancies